Stock Price Quote

ABBOTT INDIA LTD.

NSE : ABBOTINDIABSE : 500488ISIN CODE : INE358A01014Industry : Pharmaceuticals & DrugsHouse : Abbott India - MNC
BSE26946.00197.55 (+0.74 %)
PREV CLOSE ( ) 26748.45
OPEN PRICE ( ) 26771.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 555
TODAY'S LOW / HIGH ( )26663.35 27200.00
52 WK LOW / HIGH ( )20594.25 29628.15
NSE27120.80409.75 (+1.53 %)
PREV CLOSE( ) 26711.05
OPEN PRICE ( ) 26858.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 33995
TODAY'S LOW / HIGH( ) 26715.00 27229.90
52 WK LOW / HIGH ( )20605.05 29638.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 22-08 1944
Management Info
Munir Shaikh - Chairman - Managing Director
Registered Office

Address Unit No. 3,Corporate Park,Sion Trombay Road,
Mumbai,
Maharashtra-400071

Phone 022-50461000 / 2000 / 67978888

Email webmasterindia@abbott.com / investorrelations.india@abbott.com

Website www.abbott.co.in

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

27Mar Abbott India informs about newspaper a
Pursuant to Regulation 47 of the Securities and Exchange Board of India..
19Mar Abbott India informs about resignation
With reference to its earlier communication dated December 19, 2023, whe..
15Mar Abbott India informs about change in s
Pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Sche..
13Mar Abbott India informs about change in d
Pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Sche..
13Mar Appointment Of Internal Auditors For
Appointment of Internal Auditors for the financial year 2024-25

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit3109.89494.1
Gross Profit 4221.6 12738.2
Operating Profit 443313597.8
Net Sales 14371.453487.3

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi India (BSE)
peergroup  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
peergroup  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
peergroup  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
Glaxosmithkline Phar (BSE)
peergroup  1943.10 (3.26%)
M.Cap ( in Cr)32917.29
RPG Life Sciences (BSE)
peergroup  1530.20 (3.92%)
M.Cap ( in Cr)2530.80

Shareholding Pattern

PROMOTERS 74.99%
MUTUAL FUNDS/UTI 7.26%
NON-INSTITUTION 16.09%
FI/BANKS/INSURANCE 1.35%
GOVERNMENT 0%
FII 0%

About Abbott India Ltd.

Abbott India Ltd. was incorporated in the year 1944. Its today's share price is 26946. Its current market capitalisation stands at Rs 57258.37 Cr. In the latest quarter, company has reported Gross Sales of Rs. 54896.3 Cr and Total Income of Rs.55030.2 Cr. The company's management includes Mahadeo Karnik, Sangeeta Shetty, Sabina Ewing, Kaiyomarz Marfatia, Ambati Venu, Shalini Kamath, Sudarshan Jain, Anisha Motwani, Munir Shaikh.

It is listed on the BSE with a BSE Code of 500488 , NSE with an NSE Symbol of ABBOTINDIA and ISIN of INE358A01014. It's Registered office is at Unit No. 3,Corporate Park,Sion Trombay RoadMumbai-400071, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, Deloittee Haskins & Sells, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.